Asked what this has to do with the pivotal trial and got this response.
Thank you for your enquiry. Our commercialisation strategy to date has predominantly focused on the US market. Study NCT06510855 will further our commercialisation plans in Europe in addition to providing additional data to support the premarket application (PMA) to the FDA for both aortic stenosis and a potential secondary indication in valve-in-valve patients.
Asked what this has to do with the pivotal trial and got this...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
-0.650(4.44%) |
Mkt cap ! $295.9M | |||
| Open | High | Low | Value | Volume |
| $14.00 | $14.40 | $13.11 | $401.7K | 28.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2157 | $13.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.25 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |